Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Steven M. Garner"'
Autor:
Steven M. Garner, Jillian V. Krings, Emily C. Hoehn, Erin N. Lofton, Lyndsey M. Rose, Lee R. Cavedine, Brendan M. Lahm, Kaleb Collver, Kaitlyne Powers, Lindsey Herishen, Alastair J. King
Publikováno v:
Cancer Research. 83:2769-2769
It is estimated that in the U.S. alone, roughly $200 billion are spent each year on cancer drug discovery. Although this spending is significant, we have still to find truly resilient and enduring treatment plans for a significant percentage of human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::034547f27b6e7579776772a3e9ea8fb7
https://doi.org/10.1158/1538-7445.am2023-2769
https://doi.org/10.1158/1538-7445.am2023-2769
Autor:
Luciano Galdieri, Justin Lipner, Steven M. Garner, Jillian Krings, Emily Hoehn, Brendan Lahm, Kaleb Collver, Kaitlyne Powers, Alastair J. King
Publikováno v:
Cancer Research. 83:2770-2770
Aurora kinases (Aur) are a family of serine/threonine kinases essential for genetic stability and cell division during mitosis. In humans, activity of the three paralogs (AurA, AurB, and AurC) is regulated throughout the cell cycle, with peak activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c653a9bdc26a1ea5953d745351a04d77
https://doi.org/10.1158/1538-7445.am2023-2770
https://doi.org/10.1158/1538-7445.am2023-2770
Autor:
Sharlene Velichko, Alison O'Mahony, Alastair J. King, Jesse J. Parry, Justin H. Lipner, Alyssa M. Croff, Steven M. Garner
Publikováno v:
Molecular Cancer Therapeutics. 18:C116-C116
Although recent innovations in anti-cancer therapies have led to better treatment strategies and improved patient outcomes, cancer is still one of the leading causes of morbidity and mortality, globally. Thus, the need to pursue better and safer ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10cfe732e6f2e4673cb88c7b168662ca
https://doi.org/10.1158/1535-7163.targ-19-c116
https://doi.org/10.1158/1535-7163.targ-19-c116
Autor:
Tracy Lu, Vanessa L. Norman, Lee R. Cavedine, Kayla A. Stehle, Steven M. Garner, Natiya E. Robinson, Alyssa M. Croff, Jesse J. Parry, Victoria V. McBain, Kristin C. Dempsey, Joseph T. Murphy, Charles R. Wageman, Brogan A. Epkins, Alastair J. King
Publikováno v:
Cancer Research. 79:4245-4245
High-throughput, cell-based drug screening platforms are essential to guiding drug discovery programs and can rapidly generate large amounts of pharmacological information about a candidate drug. Drug response data combined with genomic and phenotypi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b1877cd935a71a2e4979be6b16ca31b
https://doi.org/10.1158/1538-7445.am2019-4245
https://doi.org/10.1158/1538-7445.am2019-4245
Autor:
Alastair J. King, Natiya E. Robinson, Kayla A. Stehle, Steven M. Garner, Jesse J. Parry, Vanessa L. Norman, Kristin C. Dempsey, Joseph W. Murphy, Charles R. Wageman, Alyssa M. Croff, Lee R. Cavedine, Tracy Lu, Brogan A. Epkins, Victoria V. McBain
Publikováno v:
Cancer Research. 79:2073-2073
Oncology drugs with clinical utility for the treatment of breast cancer span a wide range of different mechanisms and cancer type profiles. Anti-cancer therapies have come a long way from the early use of broad spectrum, cytotoxic agents, with mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65da7b56300a4d0b4d38de7f203443bb
https://doi.org/10.1158/1538-7445.am2019-2073
https://doi.org/10.1158/1538-7445.am2019-2073
Autor:
Natiya E. Robinson, Alyssa M. Croff, Vanessa L. Norman, Alastair J. King, Brogan A. Epkins, Lee R. Cavedine, Steven M. Garner, Jesse J. Parry, Kristin C. Dempsey, Charles R. Wageman, Usha Warrior
Publikováno v:
Cancer Research. 78:2260-2260
Using drug response data, generated by the OncoPanelTM cell-based profiling service, we investigated the differences between traditional and normalized growth rate inhibition (GR) metrics in drug sensitivity classification and predictive genomic biom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e38cfbfa89a47624d143a3893c53e5d6
https://doi.org/10.1158/1538-7445.am2018-2260
https://doi.org/10.1158/1538-7445.am2018-2260
Autor:
Usha Warrior, Timothy J. Sindelar, Natiya E. Robinson, Vanessa L. Norman, Kristin C. Dempsey, Brogan A. Epkins, Alastair J. King, Charles R. Wageman, Lee R. Cavedine, Steven M. Garner, Jesse J. Parry, Alyssa M. Croff
Publikováno v:
Cancer Research. 78:1391-1391
Given the importance and significance of targeting mutations and epigenetic modification in cancer therapy, we sought to expand on our ability to test drugs with epigenetic modulatory abilities by increasing the exposure time of drugs against cell li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41557ed67d82a04d983a177cb5d99836
https://doi.org/10.1158/1538-7445.am2018-1391
https://doi.org/10.1158/1538-7445.am2018-1391
Autor:
Usha Warrior, Timothy J. Sindelar, Lee R. Cavedine, Brogan A. Epkins, Alyssa M. Cracchiolo, Samantha C. Burkart, Steven M. Garner, Jesse J. Parry, Alastair J. King, Charles R. Wageman
Publikováno v:
Cancer Research. 77:5075-5075
In recent years, epigenetic target inhibitors have emerged as viable therapeutics for treating various types of cancers. Testing of the epigenetic inhibitors in cell proliferation assays revealed that inhibition of many epigenetic targets resulted in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d60d71ab993878400141caee55d9a6c
https://doi.org/10.1158/1538-7445.am2017-5075
https://doi.org/10.1158/1538-7445.am2017-5075
Autor:
Stephen P. Davies, Andy Plater, Alyssa M. Cracchiolo, Anna M. Woodward, Samantha C. Burkart, Charles R. Wageman, Usha Warrior, Steven M. Garner, Jesse J. Parry, Alastair J. King, Lee R. Cavedine, Timothy J. Sindelar, Brogan A. Epkins
Publikováno v:
Cancer Research. 77:2116-2116
Profiling of inhibitors for eventual therapeutic use is an essential part of drug discovery and development. Evaluating the in vitro potency of kinase inhibitors in a wide panel of enzyme assays is critical, not only to guiding SAR knowledge for impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75c78cfd01475daa4b6b1689c5aed167
https://doi.org/10.1158/1538-7445.am2017-2116
https://doi.org/10.1158/1538-7445.am2017-2116
Autor:
Samantha C. Burkart, Steven M. Garner, Jesse J. Parry, Usha Warrior, Timothy J. Sindelar, Brogan A. Epkins, Lee R. Cavedine, Charles R. Wageman, Alyssa M. Cracchiolo, Alastair J. King
Publikováno v:
Cancer Research. 77:5787-5787
The OncoPanel™ service has established 100 genomically-characterized human tumor cell lines as targets for the screening of compounds in 3D spheroid models. We sought to (1) expand the cell line capability of the service and (2) validate the cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e7123f9f7bfd0d2bb2e0649be6fb5b5
https://doi.org/10.1158/1538-7445.am2017-5787
https://doi.org/10.1158/1538-7445.am2017-5787